FDA approved implantable device opens doors for technology within the body

Cara Livernois | | Health Exec | Economics

Nucleus 7, a device from Apple and Cochlear, a hearing assistance company, is a surgically implanted sound processor connected to the iPhone to improve the quality of life for impaired patients.

The Nucleus 7 is in a unique position to offer technological care to patients everywhere. The U.S. Food and Drug Administration approved the implant, paving the way for other technologies to push the boundaries of technology within the human body.

“The approval of the Nucleus 7 Sound Processor is a turning point for people with hearing loss, opening the door for them to make phone calls, listen to music in high-quality stereo sound, watch videos and have FaceTime calls streamed directly to their cochlear implant,” Cochlear CEO Chris Smith said in a statement.

Read the full story below:

iCyborg: Apple Just Announced The First Mass Market Cyborg Enhancement

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.